Orthofix Medical (OFIX) 10% Owner LLC Buys $1M of Stock

Juniper Investment Company, LLC purchased 120,000 shares of Orthofix Medical Inc. (OFIX) on September 18, 2026, for approximately $1,048,716. This acquisition raises Juniper's stake in the company to about 4.4 million shares, valued at roughly $41.8 million based on the latest market data.

Inside Juniper Investment Company's Trade

Juniper Investment Company, a beneficial owner of more than 10% of Orthofix, bought the shares at an average price of $8.74. This move comes as the stock trades near its 52-week low of $8.50, suggesting a strategic buy in a challenging market for the healthcare sector.

Other Institutional Activity in Orthofix

Other institutional investors have also adjusted their positions in Orthofix. Engine Capital Management, LP increased its holdings by 184,854 shares, bringing its total to about 4.6 million shares worth around $43.1 million. Juniper Investment Company itself added 465,690 shares in its last report, reflecting an 11.7% increase. Blackrock Inc. also added 118,691 shares, totaling approximately $31.3 million.

Orthofix Medical Inc. Stock Up 7.7%

Orthofix Medical shares closed at $8.71 on the last trading day before Juniper's purchase. The stock has been under pressure, trading just above its 52-week low of $8.50. With a market cap of approximately $364.6 million, the company faces challenges as it works to improve its profitability metrics.

Recent Earnings

In its most recent fiscal year, Orthofix reported revenue of $833.2 million, reflecting a growth rate of 3.8%. However, the company posted a net loss per share of $1.52, indicating ongoing profitability challenges. The next earnings report is scheduled for November 3, 2026, which may provide further insights into the company's performance.

Insider Buying and Selling at Orthofix Medical Inc.

In addition to Juniper's recent purchase, other insiders have been active. On September 21, 2026, Juniper Investment Company bought an additional 310,000 shares, valued at about $2.73 million. Officer Patrick G. Fisher sold 150 shares on October 1, 2026, for about $1,416.

Analysts Set New Price Targets

Analysts have mixed views on Orthofix Medical. On August 10, 2026, Canaccord Genuity maintained a "Buy" rating with a price target of $13.00, down from $18.00. Barrington Research also kept its "Outperform" rating but raised its target from $15.00 to $17.00.

About Orthofix Medical

Orthofix Medical Inc. operates in the medical technology sector, focusing on products for spinal and limb reconstruction. The company serves various international markets, aiming to improve patient outcomes through innovative medical devices.

Bottom Line

Investors should watch for Orthofix's upcoming earnings report on November 3, 2026, for updates on its performance. Juniper's recent buying activity reflects confidence in the company's long-term prospects, but ongoing profitability concerns remain an issue as indicated by the recent earnings data.